Key result
The total per patient per month medical cost for multiple sclerosis in Japan was ¥93,542, with disease-modifying therapy drugs accounting for half of the overall costs.
Observational (n=1,133)
In Japan, the total per patient per month cost for MS is ¥93 542, driven largely by disease-modifying therapies.
Japanese MS care costs are high and DMT-driven; leaves open whether targeted interventions improve value in real-world settings.
OBJECTIVE: To assist policymakers as they reflect on treatment protocols and approaches for the efficient delivery of medical care for multiple sclerosis (MS) patients in Japan. METHODS: We analyzed data from a large Japanese health insurance claims database. Using an algorithm based on diagnosis codes, all patients with a diagnosis of MS were identified; patients having a non-MS demyelinating disease were excluded from the population. MS patient data were used for cross-sectional analysis carried out on the data collected at a certain period. We identified a total of 1808 MS patients, and we analyzed data for 1133 patients with an observation period of ≥6 months from October 2013 to September 2014. Newly diagnosed MS patients were identified within the MS patients, and their data were used for longitudinal analysis, tracking each patient over a period of time. RESULTS: The total per patient per month cost for MS was ¥93 542 (US$781, €695 as of October 2015). Disease-modifying therapy drugs costs constituted half of the overall medical costs. For newly diagnosed MS patients, hospitalization costs were the largest component in the initial month, while drug costs were the largest component more than several months after the initial visit. There was a positive correlation between relapse frequency and medical cost. CONCLUSIONS: These results provide up-to-date information on the demographics, medical treatment and cost status of MS in almost real-time by using a claims database. They suggest that claims data analysis can effectively support medical policymaking.
No takes yet. Share an insight, caveat, or question.
Ogino et al. (2016) conducted an observational in Multiple sclerosis (n=1,133). Multiple sclerosis diagnosis and treatment was evaluated on Total per patient per month medical cost. The total per patient per month medical cost for multiple sclerosis in Japan was ¥93,542, with disease-modifying therapy drugs accounting for half of the overall costs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: